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INTRODUCTION
Concurrent with the major evolution of surgical techniques and 
immunosuppressant regimens, liver transplantation (LT) criteria 
for patients with hepatocellular carcinoma (HCC) have rapidly ex-
panded in the past few decades.1-3 Despite the scarcity of donor 
organs, LT is theoretically the best treatment option for patients 
with early stage HCC.4 However, tumor recurrence remains a ma-
jor cause of post-transplant death.5 Unfortunately, no adjuvant 
therapy has been shown to improve survival after LT for HCC.
Several tumor-related risk factors for HCC recurrence, such as 
high alpha-fetoprotein (AFP) levels,6,7 poor tumor differentiation,8,9 
and the presence of microscopic vascular invasion (MiVI),10,11 have 
been extensively demonstrated to be strong risk factors for poor 
outcomes after LT. Immunosuppression-related risk factors for tu-
mor recurrence have also been reported. Vivarelli et al.12,13 noted 
that overexposure to calcineurin inhibitors (CNIs; tacrolimus and 
cyclosporin) increased the risk of HCC recurrence after LT. Con-
versely, in a recent systematic review, Grigg et al.14 reported that 
mammalian target of rapamycin inhibitors (mTORi)-based immu-
nosuppression might reduce recurrence rates compared with stan-
dard CNI-based therapy. Accordingly, mTORi have been consid-
ered an alternative immunosuppressive agent to CNIs.
However, despite the expanding use of mTORi-based therapy, it 
remains unclear whether mTORi have a direct oncologic advan-
tage or whether their benefits simply reflect the indirect effects of 
reducing CNI levels. Furthermore, no universally accepted guide-
lines exist for mTORi usage after LT for HCC. Immunosuppression 
schedules that vary considerably between centers and the wide 
range of target trough blood levels make it difficult to verify the 
long-term oncologic effects of mTORi.
At our institution, we have been following a unified immuno-
suppressive protocol for mTORi usage for several years. In the 
present study, we reviewed our experience with mTORi (particu-
larly everolimus [EVR]) after LT in patients with HCC to evaluate 
the impact of EVR on long-term outcomes, specifically time to re-
currence (TTR) and overall survival (OS). We also investigated 
general prognostic factors for TTR and OS after LT for HCC.
Background/Aims: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver 
transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Methods: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were 
retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with 
calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR 
group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared 
between the groups, and prognostic factors for TTR and OS were evaluated.
Results: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of 
tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). 
Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and 
OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 
0.248; P=0.001) and OS (HR, 0.145; P<0.001).
Conclusions: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for 
HCC. These findings warrant further investigation in a well-designed prospective study. (Clin Mol Hepatol 2021;27:589-
602)
Keywords: Hepatocellular carcinoma; Liver transplantation; Immunosuppression; Recurrence; Survival
Study Highlights
We reviewed data from 303 consecutive patients with hepatocellular carcinoma who underwent liver transplantation. After transplantation, patients 
received a CNI plus everolimus or a CNI without everolimus. Although patients who received a CNI plus everolimus had more aggressive tumor biol-
ogy, they had better time to recurrence and overall survival than those who received a CNI without everolimus. On multivariable analysis, use of 
everolimus was identified as an independent prognostic factor for improved time to recurrence and overall survival.
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MATERIALS AND METHODS
Patient and data collection
This study was approved by the institutional review board of 
Severance Hospital (reference number, 4-2020-0808). The data 
were prospectively recorded in our institution’s clinical database. 
The data from consecutive patients who had undergone LT for 
HCC from January 2012 to July 2018 at Severance Hospital, Seoul, 
Korea, were retrospectively reviewed. All the patients had histo-
logically confirmed pure HCC; we excluded patients with mixed 
HCC-cholangiocarcinoma tumors. Patients who had died within 
1 month after LT and patients who had withdrawn from the pro-
tocol during treatment because of intolerable side effects from 
the drugs (CNI or EVR) were excluded. Information regarding pa-
tient demographics (recipient age and sex) and other clinicopath-
ologic features (underlying liver disease, preoperative blood AFP 
level, model for end-stage liver disease [MELD] score, graft type, 
fulfillment of Milan criteria, tumor size and number, and MiVI) 
were extracted from the database. All the resected specimens 
were subjected to histologic analysis.
Figure 1. Study flow diagram. LT, liver transplantation; EVR, everolimus; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.
Total patients (n=315)
Excluded (n=12)
√ Mortality within 1 month after LT
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Figure 2. Immunosuppression protocol after liver transplantation in patients with hepatocellular carcinoma. The target blood trough level of tacroli-
mus for the non-EVR group was maintained at 5–8 ng/mL (blue bar). The target blood trough level of tacrolimus for the EVR group was changed from 
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Changes in the immunosuppression protocols over 
time
At our institution, all the patients who had undergone LT before 
2012 were treated with CNIs as their primary immunosuppressive 
regimen. However, with increasing recognition of mTORi and their 
prognostic relevance for survival, we began to use EVR in combi-
nation with CNIs in January 2012. During the initial combination 
period (January 2012 to May 2015), because of our limited experi-
ence with EVR, we used EVR only in high-risk patients with unfa-
vorable prognostic factors for tumor recurrence, such as patients 
exceeding the Milan criteria or those with pathologically con-
firmed MiVI. Since June 2015, EVR has been covered by Korean 
National Insurance for combination treatment with tacrolimus af-
ter LT, allowing us to gradually expand the use of EVR to low-risk 
patients. For this study, we divided patients into two groups ac-
cording to EVR usage: non-EVR group (CNI alone or CNI plus my-
cophenolate mofetil) and EVR group (CNI plus EVR) (Fig. 1).
Differences in target trough blood levels between 
the non-EVR and EVR groups
Our immunosuppressive protocol for patients with HCC under-
going LT is shown in Figure 2. Induction immunosuppression ther-
apy was performed with basiliximab injected on the day of LT and 
postoperative day 4 in all recipients. Two high-dose boluses of 
methylprednisolone (500 mg) were infused intravenously immedi-
ately following portal vein and hepatic artery reperfusion during 
LT. After LT, intravenous methylprednisolone was tapered to 
60 mg/day over 4 days and then switched to oral prednisolone 
(30 mg/day) on day 5. Oral prednisolone was gradually tapered, 
reaching 10 mg/day at 4 weeks post-LT. Maintenance immuno-
suppression comprised tacrolimus-based immunosuppression with 
or without EVR. EVR was usually initiated at 1 mg twice per day 
starting at 4 weeks after LT. The target trough blood level of EVR 
was 3–5 ng/mL. The target trough level of tacrolimus without 
EVR (non-EVR group) was the conventional range of 5–8 ng/mL 
throughout the study, while the target trough level for the reduced 
tacrolimus dose (EVR group) was 3–5 ng/mL after initiating EVR.
Post LT follow-up
All the patients were followed up according to our institutional 
post-LT protocol. All the patients were followed monthly to assess 
their immunosuppressive drug trough levels until 12 months after 
discharge. According to those results, the dosage of the CNI or 
EVR was adjusted to the target trough level. Imaging studies, in-
cluding dynamic computed tomography and/or ultrasound, were 
performed every 3 to 6 months after LT. Measurement of the se-
rum AFP levels was also followed by imaging studies. Tumor re-
currence was defined as suspicious imaging findings or a patho-
logically confirmed tumor from biopsy or surgery. The primary 
endpoint of this study was TTR, while the secondary endpoint 
was OS. TTR was defined as the time from the date of LT to the 
time of recurrence. Patients with no recurrent disease were cen-
sored at the last time at which they were known to be recurrence-
Table 1. Baseline patient characteristics 
Characteristic Value (n=303)
Recipient age (years) 56 (34–73)
Sex, male:female 247:56
Donor age (years) 34 (11–71)
Preoperative AFP level (ng/mL) 59.8±210.6
MELD score 12.7±7.2









ABO incompatible 47 (15.5)
Number of tumors 3.6±4.6
Maximum tumor size (cm) 2.5±1.9
Microscopic vascular invasion 79 (26.1)
Immunosuppression regimen
CNI alone or CNI plus MMF 189 (62.4)
CNI plus everolimus 114 (37.6)
Exceeding Milan criteria 77 (25.4)
Recurrence 49 (16.2)
Follow-up duration (months) 37.1 (1.2–80.2)
Values are presented as mean±standard deviation, median (range), or 
number (%) unless otherwise indicated.
AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; HCC, he-
patocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, 
non-B, non-C; LDLT, living donor liver transplantation; DDLT, deceased donor 
liver transplantation; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.
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free. OS was defined as the duration from the date of LT to pa-
tient death or the study end date.
Statistical analysis
Categorical data were summarized and reported as frequencies 
and percentages and were compared using chi-squared test or 
Fisher’s exact test, as appropriate. Continuous variables were 
summarized and reported as means±standard deviation or medi-
ans and interquartile range; they were compared using Student’s t  
test or the Mann-Whitney U test, depending on whether the vari-
ables had a normal distribution. Survival curves were created us-
ing the Kaplan-Meier method and compared using the log-rank 
test. Factors associated with TTR and OS were identified using 
univariable and multivariable Cox proportional hazards regression 
models. All variables significant (P<0.05) in univariable analysis 
were entered into step-down Cox proportional hazards regression 
analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) 
were calculated for all the regression results. All the analyses 
were performed using SPSS version 23 (IBM Corporation, Ar-
monk, NY, USA). Propensity score analysis and matching were 
used with the psmatching program. All analyses were performed 
in R 3.3.3 software (R Foundation for Statistical Computing, Vien-
na, Austria). P  values <0.05 considered statistically significant.
RESULTS
From January 2012 to July 2018, 315 patients underwent LT for 
HCC at Severance Hospital. We excluded 12 patients who met the 
aforementioned exclusion criteria. Among the 303 patients re-
maining in the study, 114 (37.6%) were included in the EVR group 
and 189 (62.4%) were included in the non-EVR group.
Baseline characteristics
Table 1 shows the baseline characteristics of the 303 patients 
included in the study. Of these, 247 (81.5%) were men and 56 
Table 2. Comparison of the clinicopathologic characteristics between the groups
Characteristic Non-EVR group (n=189) EVR group (n=114) P-value
Recipient age (years) 55.5±7.4 55.8±8.2 0.814
Sex, male:female 152:37 95:19 0.527
Donor age (years) 36.2±12.7 35.7±11.4 0.065
Preoperative AFP level (ng/mL) 66.3±246.6 49.1±131.2 0.499
MELD score 12.7±7.4 12.6±7.0 0.966
Child-Pugh class, A:B:C 103:60:26 63:36:15 0.987
Etiology 0.518
HBV 149 (78.8) 89 (78.1)
HCV 14 (7.4) 10 (8.8)
Alcohol-related 15 (7.9) 12 (10.5)
NBNC 11 (5.8) 3 (2.6)
LDLT 127 (67.2) 87 (76.3) 0.091
ABO incompatible 31 (16.4) 16 (14.0) 0.581
Number of tumors* 3.0±3.1 4.6±6.2 0.003
Maximum tumor size (cm)* 2.5±1.6 2.5±2.3 0.821
Microscopic vascular invasion* 40 (21.2) 39 (34.2) 0.017
Exceeding Milan criteria* 40 (21.2) 37 (32.5) 0.029
Recurrence 38 (20.1) 11 (9.6) 0.017
Values are presented as mean±standard deviation or number (%) unless otherwise indicated.
EVR, everolimus; AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-B, non-C; LDLT, 
living donor liver transplantation.
*These variables were assessed by pathological examination of the explanted liver.
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(18.5%) were women, with a median age of 56 years (range, 34–
73). All the patients had histologically confirmed HCC. Overall, 
238 patients (78.5%) were positive for hepatitis B virus infection, 
and 24 (7.9%) were positive for hepatitis C virus infection. The 
mean maximum tumor size was 2.5 cm, and 47 patients (15.5%) 
had undergone ABO-incompatible LT. Living donor LT was per-
formed in 216 patients (71.3%), whereas 87 patients (28.7%) re-
ceived deceased donor grafts. Tumors exceeded the Milan criteria 
in 77 patients (25.4%). The median follow-up period was 37.1 
months (interquartile range, 1.2–80.2).
Clinicopathologic characteristics according to EVR 
usage
The clinicopathologic characteristics of patients in the non-EVR 
and EVR groups are shown in Table 2. Compared with non-EVR 
group, the EVR group had a significantly lower donor age (P=0.021) 
and a higher percentage of patients with MiVI (P=0.017) or ex-
ceeding the Milan criteria (P=0.029). Patients in the EVR group 
also had a higher number of tumors than those in the non-EVR 
group (P=0.003). Other clinicopathologic parameters did not dif-
fer significantly between the EVR and non-EVR groups.
Figure 3. Kaplan-Meier survival curves of patients who had undergone liver transplantation for hepatocellular carcinoma. Time to recurrence (A) and 
overall survival (B) according to EVR use before propensity score matching. Time to recurrence (C) and overall survival (D) according to EVR after pro-

















0 12 24 36 48 60 72 84









































0 12 24 36 48 60 72 84


























Incheon Kang, et al. 
Everolimus in liver transplantation
http://www.e-cmh.org https://doi.org/10.3350/cmh.2021.0038
Actual drug exposure
The mean trough tacrolimus levels within the first months after 
LT were not significantly different between the groups (non-EVR: 
10.56±2.15 ng/mL; EVR: 10.97±2.28 ng/mL; at 7 days P=0.876). 
However, the introduction of EVR was followed by a stepwise de-
crease in tacrolimus exposure in the EVR group. The mean trough 
tacrolimus level was reduced from 10.96±3.67 ng/mL at initial to 
3.15±2.31 ng/mL at 24 months. By contrast, the mean trough ta-
crolimus level in the non-EVR group remained at approximately 
6–7 ng/mL from 4 months onward. Thus, the trough tacrolimus 
concentrations remained significantly reduced in the EVR group 
during the follow-up period compared with those in the non-EVR 
group (Supplementary Fig. 1A).
The mean trough level of EVR at 1 month post-LT was 2.12±1.23 
ng/mL but increased and persisted within the target range (3–5 
ng/mL) from 2 months onward: 3.05±1.38 ng/mL at 2 months, 
4.16±1.45 ng/mL at 4 months, 3.89±2.36 ng/mL at 6 months, 
4.35±1.84 ng/mL at 8 months, 3.82±1.69 ng/mL at 10 months, 
3.32±1.96 ng/mL at 12 months, and 3.45±1.78 ng/mL at 24 
months (Supplementary Fig. 1B).
Survival differences between the non-EVR and EVR 
groups 
During the median follow-up of 37.1 months, 49 patients 
(16.2%) developed tumor recurrence and 53 (17.5%) died. When 
examining the entire cohort, the 1-, 3-, and 5-year TTR rates were 
90.1%, 81.5%, and 80.0%, respectively, while the 1-, 3-, and 
5-year OS rates were 91.2%, 82.4%, and 77.7%, respectively. The 
TTR curves for the EVR and non-EVR groups are shown in Figure 3A. 
TTR was significantly longer in the EVR group than in the Non-
EVR group (P=0.029). The OS curves of patients according to EVR 
are shown in Figure 3B. Similar to TTR, OS was significantly lon-
ger in the EVR group (P<0.001).
Table 3. Clinicopathologic characteristics between the groups after PSM
Characteristic Non-EVR group (n=180) EVR group (n=90) P-value
Recipient age (years) 55.5±7.4 55.8±8.2 0.814
Sex, male:female 147:33 72:18 0.742
Donor age (years) 36.2±12.7 35.7±11.4 0.065
Preoperative AFP level (ng/mL) 56.7±211.8 49.3±135.8 0.523
MELD score 12.6±7.3 12.3±7.1 0.589
Child-Pugh class, A:B:C 98:59:23 50:30:10 0.925
Etiology 0.742
HBV 141 (78.3) 74 (82.2)
HCV 13 (7.2) 7 (7.8)
Alcohol-related 15 (8.3) 6 (6.7)
NBNC 11 (6.1) 3 (3.3)
LDLT 126 (70.0) 71 (78.9) 0.121
ABO incompatible 31 (17.2) 13 (14.4) 0.560
Number of tumors* 3.0±3.1 3.2±3.0 0.859
Maximum tumor size (cm)* 2.5±1.6 2.3±1.5 0.799
Microscopic vascular invasion* 39 (21.7) 20 (22.2) 0.917
Exceeding Milan criteria* 40 (22.2) 21 (23.3) 0.837
Recurrence 37 (20.6) 1 (1.1) <0.001
Values are presented as mean±standard deviation or number (%) unless otherwise indicated.
PSM, propensity score matching; EVR, everolimus; AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; HBV, hepatitis B virus; HCV, hepatitis C 
virus; NBNC, non-B, non-C; LDLT, living donor liver transplantation.
*These variables were assessed by pathological examination of the explanted liver.
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Propensity score-matched comparison of non-EVR 
and EVR groups
Since this study was retrospectively designed in the first place, 
there were no consistent criteria for the selection of EVR over 
time. To minimize the selection bias and balance the differences 
in the baseline covariates between the non-EVR and EVR groups, 
we conducted propensity score matching (PSM) analysis. TTR and 
OS were compared between the two groups utilizing PSM.
After the 1:2 matching, 270 patients were selected and divided 
into propensity-matched EVR group (n=90) and propensity-matched 
non-EVR group (n=180). Table 3 summarizes the clinicopathologic 
Figure 4. Subgroup analysis according to the presence of MiVI. Time to recurrence (A) and overall survival (B) according to EVR use in patients without 
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characteristics between the two groups after PSM. The baseline 
variables were well balanced, and there were no significant clinico-
pathologic characteristics between the groups. In the matched pop-
ulation, cases with EVR had better TTR and OS (P<0.001) in com-
parison with cases in the non-EVR cohort (Fig. 3C, D). The result 
after PSM confirmed that the difference in survival rates between 
the groups was more remarkable than that before PSM.
Subgroup analysis of survival stratified by MiVI and 
Milan criteria
To evaluate the effects of EVR in low-risk versus high-risk pa-
Figure 5. Subgroup analysis according to Milan criteria. Time to recurrence (A) and overall survival (B) according to EVR use in patients within Milan 
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tients, we performed subgroup analysis based on MiVI status 
(Supplementary Fig. 2) and Milan criteria (Supplementary Fig. 3), 
respectively. Low-risk patients were defined as patients without 
MiVI or within Milan criteria, and high-risk patients were defined 
as patients with MiVI or above Milan criteria.
In patients without MiVI (n=223), the EVR group had substan-
tially better TTR (P=0.005) and OS (P=0.001) than the non-EVR 
group (Fig. 4A, B). In patients with MiVI (n=80), the two groups 
had similar TTR (P=0.069; Fig. 4C), but the EVR group had a sig-
nificantly longer OS (P=0.015; Fig. 4D). In patients within Milan 
criteria (n=226), the EVR group had substantially better TTR 
(P=0.001) and OS (P=0.004) than the non-EVR group (Fig. 5A, B). 
In patients above Milan criteria (n=77), no statistically significant 
difference in TTR (P=0.655; Fig. 5C) was found between the EVR 
and non-EVR groups, but the EVR group had significantly longer 
OS (P=0.015; Fig. 5D).
Posttransplant complications
Surgical and immunological complications for the two groups 
are listed in Table 4. During the follow-up period, 25 cases 
(13.2%) and 15 cases (13.1%) of suspected acute cellular rejection 
Table 4. Posttransplant complications
Complication Non-EVR group (n=189) EVR group (n=114) P-value
Suspected acute cellular rejection 25 (13.2) 15 (13.1) 0.986
Steroid-resistant rejection 0 (0.0) 0 (0.0) -
Biliary complications 40 (21.2) 21 (18.4) 0.564
Hepatic artery stenosis 0 (0.0) 0 (0.0) -
Hepatic artery thrombosis 3 (1.6) 0 (0.0) -
Portal vein thrombosis 3 (1.6) 1 (0.9) 0.600
Wound infection 24 (12.7) 13 (11.4) 0.739
Dyslipidemia 39 (20.6) 39 (34.2) 0.009
Proteinuria 36 (19.0) 37 (32.5) 0.008
Mouth ulcers 8 (4.2) 11 (9.6) 0.060
Renal failure 2 (1.0) 1 (0.9) 0.877
Values are presented as number (%).
EVR, everolimus.
Table 5. Prognostic factors for time to recurrence
Factor
Univariable analysis Multivariable analysis
HR P-value HR (95% CI) P-value
Recipient age 0.968 0.053 - -
Male sex 2.048 0.129 - -
Donor age 0.995 0.650 - -
AFP level >50 ng/mL 3.013 <0.001 2.320 (1.235–4.358) 0.009
LDLT 0.977 0.941 - -
Tumor size >3 cm 3.203 <0.001 2.272 (1.173–4.399) 0.015
Number of tumors 1.081 <0.001 1.077 (1.038–1.117) <0.001
MELD score 0.983 0.484 - -
Exceeding Milan criteria 2.908 <0.001 - -
Everolimus use 0.481 0.033 0.248 (0.113–0.543) 0.001
Microscopic vascular invasion 4.642 <0.001 3.361 (1.824–6.194) <0.001
HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; LDLT, living donor liver transplantation; MELD, model for end-stage liver disease.
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were observed in the non-EVR and EVR groups, respectively. All 
patients with acute cellular rejection were treated with steroid 
pulse therapy. Three cases in the non-EVR group developed he-
patic artery thrombosis (HAT) versus none in the EVR group. There 
were no statistically significant differences between the EVR and 
non-EVR groups in the occurrence rate of suspected acute cellular 
rejection; biliary complications, including biliary stricture and leak; 
portal vein thrombosis; wound infection; mouth ulcers; and renal 
failure. Dyslipidemia (P=0.009) and proteinuria (P=0.008) were 
significantly more frequent adverse effects in the EVR group than 
in the non-EVR group.
Prognostic factors for time to recurrence
On univariable analysis, prognostic factors significantly associ-
ated with a worse TTR were an AFP level >50 ng/mL, tumor size 
>3 cm, higher number of tumors, exceeding Milan criteria, EVR 
use, and the presence of MiVI. In multivariable analysis, the fol-
lowing were identified as independent prognostic factors for TTR: 
AFP >50 ng/mL (HR, 2.320; 95% CI, 1.235–4.358; P=0.009), tumor 
size >3 cm (HR, 2.272; 95% CI, 1.173–4.399; P=0.015), a higher 
number of tumors (HR, 1.077; 95% CI, 1.038–1.117; P<0.001), 
the presence of MiVI (HR, 3.361; 95% CI, 1.824–6.194; P<0.001), 
and EVR use (HR, 0.248; 95% CI, 0.113–0.543; P=0.001) (Table 5). 
Exceeding Milan criteria was excluded from the multivariable 
analysis because it was designated as an overlapping factor with 
tumor size and tumor numbers.
Prognostic factors for overall survival
Univariable analysis showed that an AFP level >50 ng/mL, tu-
mor size >3 cm, a higher number of tumors, a higher MELD score, 
exceeding Milan Criteria, the presence of MiVI, and EVR use af-
fected OS. In multivariable analysis, the following were identified 
as independent prognostic factors for OS: an AFP level >50 ng/mL 
(HR, 2.120; 95% CI, 1.127–3.987; P=0.020), a higher number of 
tumors (HR, 1.059; 95% CI, 1.013–1.106; P=0.011), a higher 
MELD score (HR, 1.044; 95% CI, 1.007–1.083; P=0.019), the 
presence of MiVI (HR, 1.976; 95% CI, 1.073–3.640; P=0.029), 
and EVR use (HR, 0.145; 95% CI, 0.055–0.381; P<0.001) (Table 6).
DISCUSSION
Despite major advances in transplant immunosuppressant regi-
mens in recent decades, the ideal immunosuppression protocol 
for liver transplant recipients with HCC remains debatable. The 
primary goal of immunosuppression treatment in transplantation 
is to maintain a balance between the risk of graft rejection and 
risk of immunosuppression-induced malignancy. Therefore, select-
ing the optimal immunosuppressant regimen is crucial for improv-
ing survival after LT for HCC.
Over the past decade, CNIs (tacrolimus and cyclosporin) have 
remained the primary maintenance immunosuppressants after 
LT.15 However, numerous studies have reported CNIs (particularly 
tacrolimus) as a dose-dependent factor for increasing the risk of 
Table 6. Prognostic factors for overall survival
Factor
Univariable analysis Multivariable analysis
HR P-value HR (95% CI) P-value
Recipient age 0.988 0.497 - -
Male sex 1.748 0.198 - -
Donor age 1.019 0.063 - -
AFP level >50 ng/mL 2.329 0.006 2.120 (1.127–3.987) 0.020
LDLT 0.616 0.083 - -
Tumor size >3 cm 1.866 0.029 1.329 (0.668–2.642) 0.417
Number of tumors 1.045 0.018 1.059 (1.013–1.106) 0.011
MELD score 1.037 0.022 1.044 (1.007–1.083) 0.019
Exceeding Milan criteria 1.936 0.022 - -
Everolimus use 0.238 0.001 0.145 (0.055–0.381) <0.001
Microscopic vascular invasion 2.451 0.001 1.976 (1.073–3.640) 0.029
HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; LDLT, living donor liver transplantation; MELD, model for end-stage liver disease.
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tumor recurrence after LT for HCC.12,13,16,17 Furthermore, reducing 
the tacrolimus dosage by adding EVR has been demonstrated to 
improve post-transplant renal function compared with CNI 
alone.18,19 Therefore, these results suggest that minimizing the CNI 
levels should be considered to reduce the risks of HCC recurrence 
and renal toxicity.
The anti-proliferative and anti-tumor effects of mTORi (sirolimus 
and EVR), which were introduced as alternative immunosuppres-
sant agents to CNI, have been suggested by previous animal and 
retrospective studies.20-22 Among mTORi, EVR was developed 
more recently and has more potent anti-proliferation effects than 
sirolimus.23,24 Klawitter et al.24 highlighted the substantially differ-
ent pharmacodynamic and toxicodynamic properties between si-
rolimus and EVR. For these reasons, we have incorporated EVR 
into our post-LT protocol for patients with HCC to optimize the 
immunosuppressant regimen.
Regarding the timing of EVR use, we initiate EVR in combina-
tion with the CNI 4 weeks after LT, representing the same proto-
col used in the H2304/H2307 trials involving LT.18,25 This initiation 
time was chosen because of previously reported concerns of irre-
versible kidney damage,18,26 wound healing,27,28 and HAT.29 No 
EVR-related wound healing problems or HAT was detected in any 
of our 114 patients who received EVR.
In the absence of guidelines for EVR usage, previous studies 
have attempted to use EVR in various ways, including early or late 
initiation times, as monotherapy or combination therapy, and with 
a wide spectrum of target blood trough levels. Because of these 
heterogeneous conditions, the outcomes associated with EVR us-
age have varied considerably. However, in the present study, we 
have been following a unified immunosuppressive protocol since 
2012. Based on our findings, we believe that our protocol may 
provide clinically useful guidelines for using EVR.
In the present study, the EVR group had more aggressive tumor 
biology than the non-EVR group, as reflected by a higher number 
of tumors and a higher prevalence of MiVI and cases exceeding 
Milan criteria. These factors can be used to identify patients at a 
high risk of recurrence after surgery. Unexpectedly, the EVR group 
had better TTR and OS than the non-EVR group, despite the EVR 
group having patients with more advanced tumor characteristics. 
The result after PSM showed a more dramatic improvement in the 
survival rate of the EVR group compared to the non-EVR group. 
MiVI has been identified as one of the strongest risk factors for 
poor outcomes after LT.11,30 Lim et al.10 argued that MiVI is a better 
predictor of tumor recurrence and OS in HCC than Milan criteria. 
However, MiVI can only be detected by pathologic examination 
after LT, and no evidence currently indicates that postoperative 
adjuvant therapy provides a survival benefit after LT for HCC in 
patients with pathologically confirmed MiVI.
In subgroup analysis of high-risk patients with MiVI or above 
Milan criteria, EVR use was associated with improved OS but not 
TTR. This discrepancy between OS and TTR was unexpected. One 
possibility is that EVR has no direct impact on tumor recurrence in 
high-risk patients. As with advanced HCC, tumor recurrence is 
more likely influenced by aggressive factors related to the tumor 
itself. However, the anti-tumor effects of EVR may slow the rate 
of tumor growth and progression after recurrence, contributing to 
improved OS. This result may be a crucial clue suggesting that 
EVR may be useful not only as an immunosuppressant agent but 
also as an adjuvant therapeutic agent.
In low-risk patients, EVR was clearly beneficial for both tumor 
recurrence and survival. Only one recurrence was noted among 
the 75 MiVI-negative or 77 within-Milan criteria patients who re-
ceived EVR. These results are consistent with the findings of the 
recent multicenter randomized SILVER trial, which showed that si-
rolimus was associated with improved disease-free survival in the 
first 3–5 years after LT, particularly in low-risk patients.31 Our re-
sults suggest that the anti-cancer effects of EVR are more pro-
nounced in low-risk patients than in high-risk patients and that 
immunosuppressant protocols should be tailored to individual risk 
stratification based on tumor biology. A well-designed prospec-
tive study is required to more definitively determine the role of 
EVR for HCC.
In the present study, EVR use was an independent significant 
prognostic factor for improved TTR and OS after LT for HCC. Until 
now, the anti-tumor effects in HCC patients have been considered 
to reflect reduced CNI exposure rather than direct EVR effects. To 
our best knowledge, this is the first report describing the inde-
pendent prognostic value of EVR use in patients with HCC after 
LT. To decrease the risk of bias, multiple parameters that could 
potentially impact survival were adjusted for. Unexpectedly, after 
correction for multiple variables, EVR gained more statistical 
power as an independent prognostic factor in multivariable analy-
sis. A preoperative AFP level >50 ng/mL and the presence of MiVI 
were also strong indicators of prognosis. These results are consis-
tent with the findings of previous studies.11
The current study had some limitations. The data for this retro-
spective study were extracted from medical records, and the study 
was conducted at a single institution. PSM analysis was used to 
reduce the selection bias and confounding variables between the 
groups. However, there are some selection biases due to the ret-
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rospective design of the study. Based on our findings, a well-de-
signed randomized controlled trial is required to establish the role 
of EVR for HCC. Despite these limitations, we showed potential 
survival benefits of EVR-based immunosuppressant therapy, even 
in patients with MiVI. Our findings provide a better understanding 
of the anti-cancer effects of EVR and may be helpful in selecting 
post-LT immunosuppressant agents in other patients with HCC.
In conclusion, an immunosuppression protocol comprising EVR 
combined with lower dose CNIs was associated with improved 
long-term survival after LT for HCC. EVR was particularly benefi-
cial for reducing tumor recurrence and improving survival in low-
risk patients. EVR use was identified as an independent signifi-
cant prognostic factor for improved TTR and OS after LT in 
patients with HCC. These results provide useful information to im-
prove the management of liver transplant recipients with HCC. 
Further well-designed prospective studies should be conducted to 
confirm our results.
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